

PRELIMINARY PROGRAM

Friday, 28 September 2012

09:00-18:30 **INDUSTRY SATELLITE SYMPOSIA**

14:00-17:00 **YOUNG ONCOLOGISTS (YO) MASTERCLASS**

Clinical trial protocol development

- Accelerating drug development from bench to bedside
 - Development of biomarkers: Promises and pitfalls
 - Phase I/II clinical trial design: The example of a Flims Workshop protocol
 - Clinical trial design with new targeted agents
-

17:15-18:00 **YO VESALIUS COCKTAIL**

Experience meets youth in career development

18:30-20:00 **OPENING CEREMONY**

(Open to participants, accompanying persons and exhibitors)

20:00-21:00 **WELCOME RECEPTION**

(Open to participants, accompanying persons and exhibitors)

Please note that industry-organized social events are not authorized to start before the end of the official Welcome reception.

Saturday, 29 September 2012

08:00-08:45 **YO BREAKFAST**
How to make an impact on clinical research in the early stages of your career

08:00-09:00 **CHALLENGE YOUR EXPERT SESSIONS**
How to select amongst available options for the treatment of advanced RCC

Prevention and handling of acute allergic and infusion reactions in oncology

Screening and early-detection of lung cancer

Targeted treatments in thyroid cancer

08:00-09:00 **PATIENT CASES**
Issues in the treatment of young women
– Chemotherapy for 'good risk' under 35?
– Fertility and pregnancy after CT?
– Ovarian suppression – benefits versus morbidity

The handling of toxicity in newly approved melanoma therapies
– Targeted therapy toxicities
– CTLA4 toxicities

The retroperitoneal mass: When to use which treatment
– The challenge to best assess a patient presenting with a retroperitoneal mass
– The treatment of the retroperitoneal mass once the pathology is known

09:00-10:30 **EDUCATIONAL SESSIONS**
Diagnosis and management issues in ovarian cancer
– New insights into ovarian cancer pathology
– Optimal treatment for 1st line ovarian cancer
– How to approach relapsed patients

Issues in sarcoma
– The treatment of uterine sarcomas
– The treatment of desmoids tumors
– Histology and non-histology driven therapy for treatment of soft tissues

Molecular oncology: Strategies to improve outcome in NSCLC
– Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?
– EGFR and derived treatment strategy
– Going beyond the EGFR

The current management of castrate-resistant prostate cancer (CRPC)
– Non-metastatic CRPC and asymptomatic metastatic CRPC:
 Which treatment for which patient?
– Novel hormonal therapy for CRPC
– Novel and bone targeted agents for CRPC

-
- 09:15-10:45 **SPECIAL SYMPOSIUM**
How can medical oncologists deal with the new wave of genetic information about their patients?
- Introduction
 - Challenges of dealing with next generation sequencing for hereditary cancer in clinical practice
 - Is it necessary to screen everybody for inherited cancer? When, why and how
 - How can cancer risk and genetic prediction models help oncologists in the clinics?
 - New treatment approaches in hereditary cancer: The route towards personalized care
 - Conclusions and perspectives
-
- 09:15-10:45 **ESMO/CSCO JOINT SYMPOSIUM**
Building the clinical trials of the future
-
- 09:15-10:45 **SPECIAL SESSION (ESMO DEVELOPING COUNTRIES TASK FORCE)**
Cancer pain management: First presentation of the findings of the International Collaborative Project
- Why cancer pain is an ESMO priority
 - Discrepancies in cancer pain treatment across the globe
 - The international collaborative project to evaluate the availability and accessibility of opioids for the management of cancer pain: Survey results
 - A global policy approach to freedom from cancer pain
 - Q&A
-
- 09:15-10:45 **PROFFERED PAPERS SESSION**
-
- 11:00-12:30 **EDUCATIONAL SESSIONS**
- Developments in early NSCLC**
- Advances in surgery
 - Advances in radiotherapy
 - When to use chemotherapy
- Diagnosis and management issues in melanoma**
- New insights into melanoma pathobiology
 - From chemotherapy to targeted treatment
 - Immunotherapy
- Diagnosis and management issues in pancreatic cancer**
- New insights into pancreatic cancer biopathology
 - Treatment of advanced disease
 - Treatment of locoregional disease: Adjuvant versus neoadjuvant
- Neoadjuvant treatment for breast cancers**
- In what situation is neoadjuvant treatment indicated?
 - Neoadjuvant therapy for Her2-overexpressing and triple negative breast cancers
 - Neoadjuvant therapy for ER-positive breast cancers

-
- 11:00-12:30 **SPECIAL SYMPOSIUM**
Integrating targeted treatments with tumor biology and molecular imaging in the current and future management of neuroendocrine gastrointestinal tumors
- Introduction
 - Classification and tumor biology of NETs
 - Molecular imaging of NETs
 - Peptide receptor radio therapy of NETs
 - Targeted treatment of NETs
 - Implications for clinical practice and trial design
-
- 11:00-12:30 **ESMO-EANM JOINT SYMPOSIUM**
Imaging biomarkers in the era of targeted therapies
-
- 11:00-12:30 **ESMO-ESTRO JOINT SYMPOSIUM**
Innovative approaches to the treatment of brain metastases
-
- 11:00-12:30 **PROFFERED PAPERS SESSION**
-
- 13:00-13:45 **KEYNOTE LECTURE**
Metabolic pathways supporting tumor progression
-
- 13:00-13:50 **KEYNOTE LECTURE**
HPV biology and implications in gynecological malignancies
-
- 13:00-14:00 **POSTER DISCUSSION AND POSTER SESSIONS**
-
- 14:15-15:45 **EDUCATIONAL SESSIONS**
Locally advanced disease: Treatment choice based on risk factors in head and neck cancer
- Biological risk factors
 - Optimising drug prescription
 - Dose painting for medical oncologists
- Molecular tools for decision making in breast cancers**
- What is the current state of breast cancer classification?
 - Genomic profiling to select patients for adjuvant chemotherapy
 - Developments in markers (KI67 and other markers) in treatment decision
- Diagnosis and management issues in ovarian cancer (repetition)**
- Molecular oncology: Strategies to improve outcome in NSCLC (repetition)**
- The current management of castrate-resistant prostate cancer (CRPC) (repetition)**
-
- 14:15-15:45 **SPECIAL SYMPOSIUM**
Subtyping soft tissue sarcomas for treatment approaches
- Introduction
 - Why were IGF-1R inhibitors disappointing? Should we use them in combination?
 - Successful targeting of VEGF in soft tissue sarcomas
 - Treating sarcoma (including GIST) subtypes based on molecular characteristics
 - Nutlin as a target
 - Perspectives of subtyping

PRELIMINARY PROGRAM

14:15-15:45 **PROFFERED PAPER SESSION**

14:45-15:45 **PATIENT CASES SESSION**

Clinical approaches to germline genetic testing in oncology

- Positive family history of breast and colon cancer: Diagnostic and prevention approaches
 - Challenges of testing for TP53 germline mutations
-

16:00-17:00 **PATIENT CASES SESSION**

When to treat relapsed ovarian cancer

- Surgical intervention for recurrent ovarian cancer after an asymptomatic rise in CA125: The sooner the better?
 - Maintenance therapy after relapse: Which, when and for how long?
-

16:00-17:30 **EDUCATIONAL SESSIONS**

Diagnosis and management issues in colorectal cancer

- What can molecular pathology offer for optimal decision making?
- Current adjuvant treatment
- Conceptual approaches to metastatic disease

Developments in early NSCLC (repetition)

Diagnosis and management issues in pancreatic cancer (repetition)

Neoadjuvant treatment for breast cancers (repetition)

16:00-17:30 **SPECIAL SYMPOSIA**

Molecular answers and targets on the horizon for the treatment of GU malignancies

- Introduction
- Genes, chromosomes and the treatment of bladder cancer
- Genomics in renal cancer: From science to clinical practice
- Signaling pathways, mechanisms of resistance and treatment decisions in renal cell cancer
- Molecular insights and treatment outlook for GU malignancies

Molecular neuro-oncology: New avenues in diagnosis and treatment

- Introduction
 - Anaplastic glioma: Will molecular profiling override histology?
 - Management of glioblastoma: The road towards stratified cancer care
 - The molecular dissection of medulloblastoma
 - Brain metastasis: Challenges in understanding pathogenesis and in designing clinical trials
 - Conclusions
-

16:00-17:30 **PROFFERED PAPER SESSION**

17:30 -19:30 **ESMO EXAMINATION**

18:00-20:00 **INDUSTRY SATELLITE SYMPOSIA**

PRELIMINARY PROGRAM

Sunday, 30 September 2012

08:00-08:45 **YO BREAKFAST**
How to plan and conduct a successful research fellowship abroad

08:00-09:00 **CHALLENGE YOUR EXPERT SESSIONS**
How to select amongst available options for the treatment of advanced RCC (repetition)

Prevention and handling of acute allergic and infusion reactions in oncology (repetition)

Screening and early-detection of lung cancer (repetition)

Targeted treatments in thyroid cancer (repetition)

08:00-09:00 **PATIENT CASES**
Extranodal lymphomas
– Primary CNS lymphoma
– Primary GI lymphoma

Patient compliance with drug regimes and global treatment efficacy
– CML
– Breast cancer

Treatment of trastuzumab and lapatinib resistant patients
– Medical treatment
– Management of brain metastases

08:00-09:00 **MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)**
Management of localized gastric cancer

09:00-10:30 **SPECIAL SYMPOSIA**
Pursuing the NED condition in stage IV colorectal cancer
– Introduction
– When to think of surgery plus or minus HIPEC for peritoneal carcinomatosis
– Prioritizing liver directed therapies: Surgery plus minus ablative techniques
– Integrating liver directed therapies such as embolization and IMRT into systemic treatment
– Implications for clinical practice and trial design

Re-inventing the medical treatment of advanced prostate cancer
– Immunotherapy for advanced prostate cancer: At what cost? What biomarkers for immune therapy?
– How should we use cytotoxic chemotherapy in the treatment of castration-resistant prostate cancer?
– Integrating novel endocrine therapies: Sequential or concomitant treatment?
– How should we utilize bone treatments: Bisphosphonates, denosumab and alpharadin
– Conclusions and perspectives

09:00-10:30 **PROFFERED PAPER SESSIONS**

09:15-10:15 **MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)**
Stage 1 endometrial cancer

09:15-10:45 **EDUCATIONAL SESSION**
Decision making & management of glioma: Practical considerations
– Can molecular markers help with decision making?
– Personalized surgical therapy
– Management of glioma: From evidence to practice

Molecular tools for decision making in breast cancers (repetition)

09:15-10:45 **ESMO-EACR JOINT SYMPOSIUM**
Targeted therapies: Promises, successes and failures
– Introduction
– The pi3K-mTOR pathway in cancer
– Pi3K and/or mTOR inhibitors: Current status, future directions
– Cancer: An angiogenic disease?
– Antiangiogenic therapies in the clinic: A double-edged sword?
– Conclusions

09:15-10:45 **PROFFERED PAPER SESSION**

10:45-12:45 **ESMO CLINICAL PRACTICE GUIDELINES SESSION**

11:00-12:00 **MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)**
Bulky lymphoma of the mediastinum

11:00-12:30 **EDUCATIONAL SESSIONS**
Diagnosis and management issues in colorectal cancer (repetition)

**Locally advanced disease: Treatment choice based on risk factors
in head and neck cancer (repetition)**

11:00-12:30 **SPECIAL SYMPOSIA**
Optimizing treatment in luminal breast cancer
– Introduction: Luminal A and B: How curable are they?
– How to optimise endocrine therapy
– Which luminal BC need chemotherapy?
– New targeted agents in luminal BC
– Pharmacogenetics to optimize endocrine therapy
– Conclusions: What are the challenges in luminal BC?

Molecular targets in malignant lymphomas:

From basic science to clinical practice

- Introduction
 - New antibodies in the post-Rituximab-era: Another breakthrough?
 - mTOR inhibitors and beyond: Targeting a critical pathway
 - Proteasome inhibitors: Really a targeted therapy?
 - IMiDs: Multiple pathways but how does it really work?
 - Targeted therapy in malignant lymphoma: Clinical implications and perspectives
-

11:00-12:30 **PROFFERED PAPER SESSIONS**

13:00-13:50 **KEYNOTE LECTURE**
The hallmarks of cancer revisited

13:00-14:00 **Poster Discussion and Poster sessions**

13:15-13:45 **THEATRE**
“2084” A play in three acts

14:15-15:15 **PATIENT CASES SESSION**
Getting biology into treatment
– HPV+ oropharyngeal cancer
– Medullary thyroid cancer

14:15-15:45 **EDUCATIONAL SESSIONS**
Diagnosis and management issues in lymphoma
– New insights in the pathobiology of lymphoma
– The role of PET and bone marrow examination in lymphoma staging
– New agents for the treatment of lymphoma

Updates in supportive and palliative care
– Emerging topics in anemia and cancer
– Pain management
– Depression

Issues in sarcoma (repetition)

14:15-15:45 **SPECIAL SYMPOSIUM**
Hot topics in early stage NSCLC
– Introduction
– Customized adjuvant chemotherapy: Prognostic and predictive factors
– Is there a role for targeted agents or biologicals in stage I – III NSCLC?
– Who should be considered for surgery in stage III disease and why?
– What is the optimal radiotherapy combined with chemotherapy for stage III disease?
– Summary and implications for clinical practice

14:15-15:45 **PROFFERED PAPER SESSIONS**

14:15-15:45 **AWARD SESSION**

16:00-18:00 **LATE-BREAKING ABSTRACT SESSION 1**

16:15-17:15 **PATIENT CASES SESSION**
Intensified locoregional treatment of rectal cancer
– Optimizing radiotherapy: New schedules, new fields, new beams?
– Pursuing R-0 in difficult cases
– What else on top of fluoropyrimidines as companion to RT?

16:15-17:45 **EDUCATIONAL SESSIONS**
Towards integrated management of patients with carcinoma of an unknown primary site (CUP)
– Diagnostic workup: From immuno-histochemistry to molecular profiling
– Looking for a missing primary site and its biology
– Optimal therapeutic management of patients with distinct clinicopathological CUP subsets

Diagnostic and management issues in melanoma (repetition)

-
- 16:15-17:45 **SPECIAL SYMPOSIA**
- How to integrate new drugs in the current therapeutic landscape of metastatic triple negative breast cancer**
- Introduction: Recent failures in drug development for TN mBC
 - Does molecular triage help to identify highly sensitive disease?
 - Development of new targeted agents for TNBC
 - Is there a role for new cytotoxic agents in TNBC?
 - Targeting the host in TNBC
 - Conclusion: How to improve the outcome of TNBC
- The impact of the cancer genome project and high-throughput analyses on personalized oncology: Today and tomorrow**
- Introduction
 - The molecular heterogeneity of breast tumors
 - Initial sequencing of breast cancer genomes
 - The genomic complexity of cancer: The example of multiple myeloma
 - Mutational and chromosomal surveys of pancreatic tumors
 - Conclusions

-
- 16:15-17:45 **ESMO–MASCC JOINT SYMPOSIUM**
- Integration between medical oncology and supportive care: Two sides of the same coin**
- Supportive and palliative care: Core elements of quality cancer care
 - Antiemetics: A window to translational medicine
 - GI toxicity in oncology: Evolutionary science
 - Rational therapeutic strategies for patients with pre-anorexia and anorexia
 - Q&A
 - Conclusions

-
- 16:15-17:45 **PROFFERED PAPERS SESSION**

Monday, 1 October 2012

08:00-08:45 **YO BREAKFAST**

How to write a good review article

08:00-09:00 **CHALLENGE YOUR EXPERT SESSIONS**

How to select amongst available options for the treatment of multiple myeloma

Issues in adjuvant treatment of common tumors (with a focus on breast cancer) in older adults (age > 70)

Surveillance or adjuvant treatments in stage I testis germ cell tumors

When to order a biopsy to characterize a metastatic relapse in breast cancer

08:00-09:00 **PATIENT CASES**

**A patient with EGFR mutation who progresses to reversible EGFR TKI:
What should we do?**

- New strategies in patients refractory to reversible EGFR-TKIs
- Criteria for defining resistance to EGFR-TKIs: Are RECIST appropriate?

How to optimize the sequence of multidisciplinary treatment in patients with non-resectable liver metastases and pancreatic neuroendocrine primary

- Neuroendocrine pancreatic tumors: pNETS clinical cases
- Surgical options and timing in advanced disease

Orphan tumors: An ideal niche for selective targeted therapies

- Orphan tumors definition and why selective targeted agents are of interest
 - The role of RANK ligand inhibitor in giant cell tumors
 - The role of mTOR inhibitors in astrocytoma-related to tuberous sclerosis
 - Hedgehog inhibitors in basal cell carcinomas
-

08:00-09:00 **MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)**

Sigmoid cancer and hepatic metastases

09:00-10:00 **CONTROVERSY SESSION**

09:00-10:30 **SPECIAL SYMPOSIUM**

Latest innovations in NSCLC management

- Introduction
- Personalized therapy and bio-molecular driven treatment
- Molecular mechanisms of acquired resistance to kinase inhibitors
- New strategies on the horizon
- Breakthroughs in basic research
- Implications for clinical practice

PRELIMINARY PROGRAM

09:00-10:30 **YO FORUM**

Health economics

- Introduction
- How to address the rising costs of personalized medicine in oncology
- Health systems in Europe and equality in access to oncology treatment
- Cost effectiveness analysis alongside clinical trials: A new paradigm?
- Panel Discussion

09:00-10:30 **PROFFERED PAPERS SESSION**

09:15-10:15 **MULTIDISCIPLINARY SESSION (MIS)**

What is the clinical value of isolated tumor cells and micrometastases in sentinel node?

09:15-10:45 **SPECIAL SYMPOSIA**

Emerging diagnostic and therapeutic targets in gynecological cancers: From science to clinical practice

- Introduction
- Antiangiogenics in ovarian cancer: Where are we now?
- Targeting DNA repair deficiency in ovarian and endometrial cancers
- PI3K/AKT pathways in ovarian and endometrial cancers
- Molecular imaging of gynecological cancers
- Summary and perspectives

Melanoma therapy: From frustration to enthusiasm

- Introduction
- New molecular targets in melanoma
- How to overcome resistance in mutation driven therapies
- Anti CTLA4 and predictive biomarkers
- The combination of chemo and immunotherapy: How foes become friends
- Implications for clinical practice and trial design

09:15-10:45 **PROFFERED PAPERS SESSION**

10:30-11:30 **CONTROVERSY SESSION**

10:45-12:45 **LATE-BREAKING ABSTRACT SESSION 2**

-
- 11:00-12:30 **SPECIAL SYMPOSIA**
- A paradigm shift in early drug development:
Individualizing to more patient benefit**
- The importance of patient selection in treatment efficacy
 - The role of tumor/molecular target selection in the success of a new agent
 - What is the feature of an optimal new agent: Selective target versus multi-targeted versus combination drugs
 - Biomarkers of resistance to targeted agents
 - The role of molecular imaging in early drug development
 - Conclusions and perspectives
- From biology to treatment in advanced pancreatic and gastroesophageal cancer**
- Introduction
 - Tumor markers and biology in pancreatic cancer
 - Potential clinical application and trials
 - Tumor markers and biology in gastroesophageal cancer
 - Clinical trials with biological endpoints
 - Implications for clinical practice
-
- 11:00-12:30 **ESMO-ASCO JOINT SYMPOSIUM**
- Genomics in breast cancer: Opening new doors**
- Introduction
 - Next generation DNA sequencing: First results in breast cancer
 - Gene expression profiling of breast cancer: Past and future
 - Putting genomics into clinical practice
 - Looking beyond the primary tumor
 - Conclusions
-
- 11:00-12:30 **ESMO DCTF–AORTIC–SLACOM–UICC–WHO JOINT SYMPOSIUM**
-
- 11:00-12:30 **SPECIAL SESSION (ESMO GERIATRIC ONCOLOGY FACULTY AND SIOG)**
- Geriatric oncology: Issues that also relate to cancer in younger patients**
- Introduction
 - Telomeres and ageing: Basic science for clinicians
 - Renal function: A determinant of many problems
 - The toxicity of targeted agents: Implications for care
 - Adjuvant chemotherapy for breast cancer: Limitations and results
 - Conclusions
-
- 11:00-12:30 **PROFFERED PAPERS SESSION**
-
- 12:00-13:00 **CONTROVERSY SESSION**
-
- 13:00-13:50 **KEYNOTE LECTURE**
- The characterization of lung cancer in multiple different diseases**
-
- 13:00-14:00 **POSTER DISCUSSION AND POSTER SESSIONS**

PRELIMINARY PROGRAM

14:00-15:00 **CONTROVERSY SESSION**

14:00-15:30 **ESMO-JSMO JOINT SYMPOSIUM**

Recent advances in the treatment of GI tract and liver cancer in the EU and Japan

- Introduction
 - Colorectal cancer: A new oral cytotoxic agent reappears.
 - Hepatocellular carcinoma: Present treatment strategy in Japan
 - Hepatocellular carcinoma in the EU
 - Can PET imaging help individualize the treatment of colorectal cancer patients?
 - Conclusions
-

14:00-15:30 **PROFFERED PAPERS SESSIONS**

14:15-15:15 **MULTIDISCIPLINARY INTERACTIVE SESSION**

N2 positive NSCLC

14:15-15:45 **SPECIAL SYMPOSIUM**

Evidence-based answers to critical questions on cancer screening and prevention

- Introduction: The burden of cancer in Europe – what fraction is preventable?
 - HPV elimination of cervical cancer: The novel options in vaccination and screening
 - Prostate cancer: What are the prospects and guidelines for screening and prevention?
 - Screening for colorectal cancer: European guidelines
 - Cancer registries in support of planning and assessing population based oncology outcomes
 - The implications of medical oncologists in cancer prevention
-

14:15-15:45 **SPECIAL SESSION (ESMO YO)**

Fellowships in Europe: Educational opportunities for European Young Medical Oncologists. An ESMO/SEOM/HESMO/AIOM/AERIO YO session

- Introduction
 - The broad concept of educational fellowships: From a short observer visit in a clinical service setting to long research fellowship in academic institutions
 - Where and how can I find the information I need? Practical tips from a former fellow
 - Funding opportunities in Europe: The ESMO fellowship program
 - How to write a successful fellowship grant application
 - The ESMO fellowship program: Past and future
 - Conclusions
-

14:15-15:45 **PROFFERED PAPERS SESSION**

15:30-16:30 **CONTROVERSY SESSION**

PRELIMINARY PROGRAM

16:00-17:00 **PATIENT CASES SESSION**
Less is not always more: Systemic treatment and surgery of relapsed and refractory testis cancer
– Treatment of refractory cases and late relapse
– Treatment of high risk testis cancer

16:00-17:30 **SPECIAL SYMPOSIA**
Biologically based treatment in head and neck squamous cell carcinoma (HNSCC)
– Introduction
– The importance of window of opportunity studies
– Strategies to optimize EGFR therapy
– Predictors of sensitivity and resistance mechanisms
– PARP inhibitors and other strategies in chemoradiation
– Hedgehog and other novel targets
– Implications for clinical practice and trial design

Key topics in supportive care
– Introduction
– Prevention and treatment of osteonecrosis
– How to deal with patients with active hepatitis B & C
– Influenza vaccination in cancer patients
– Thrombosis in cancer patients
– Conclusions and practical implications

16:00-18:00 **PRESIDENTIAL SYMPOSIUM**

17:00-18:00 **CONTROVERSY SESSION**

18:00-20:00 **INDUSTRY SATELLITE SYMPOSIA**

18:15-18:45 **ESMO GENERAL ASSEMBLY**

Controversy and abstract-related session content to be announced in Summer 2012

Tuesday, 2 October 2012

08:00-09:00 **CHALLENGE YOUR EXPERT SESSIONS**
How to select amongst available options for the treatment of multiple myeloma (repetition)

Issues in adjuvant treatment of common tumors (with a focus on breast cancer) in older adults (age > 70) (repetition)

Surveillance or adjuvant treatments in stage I testis germ cell tumors (repetition)

When to order a biopsy to characterize a metastatic relapse in breast cancer (repetition)

08:00-09:00 **PATIENT CASES**
Hepatocellular carcinoma (HCC)
– Locally advanced disease
– Systemic treatment of advanced disease

Managing a local recurrence of NSCLC after concurrent chemo-radiotherapy
– Salvage surgery: Indications and results
– Re-irradiation
– The role of systemic therapies

Prevention and treatment of skin toxicity
– Induced by targeted therapies
– Induced by cancer chemotherapy

09:00-13:00 **CONGRESS HIGHLIGHTS: THE BEST OF THE 37TH ESMO CONGRESS**

09:15-10:45 **EDUCATIONAL SESSIONS**
Decision making & management of glioma: Practical considerations (repetition)

Towards integrated management of patients with carcinoma of an unknown primary site (CUP) (repetition)

09:15-10:45 **SPECIAL SESSION (ESMO COMMUNITY ONCOLOGY WORKING GROUP)**
Excellence in care and chemotherapy: Goals and challenges for the oncology team
– The ESMO Community Oncology Working Group: A two-year focus on quality
– How do we measure quality in Medical Oncology? Quality indicators in oncology practice
– The right dose to the right patient: Chemotherapy adaptation in specific situations
– Beware of interaction: Ongoing medication and antineoplastic agents
– Process safety in prescription and administration of chemotherapy
– Conclusions

11:00-12:30 **EDUCATIONAL SESSIONS**
Diagnosis and management issues in lymphoma (repetition)

Updates in supportive and palliative care (repetition)